BOTULINUM TOXIN TYPE-A FOR THE TREATMENT OF ARM AND HAND SPASTICITY IN STROKE PATIENTS

Background: Focal spasticity can be a major drawback in 'the rehabilit ation of stroke patients. Previous studies suggest a beneficial effect for botulinum toxin A (BTX-A) for relief of spasticity. Objective: To evaluate the safety and efficacy of BTX-A in the treatment of spastic ity in a homogeneous group of stroke patients. Methods: In this phase III open label trial 19 stroke patients stable for ar least six months were enrolled (mean age 53.1 (SD 3.27) years; range 26-72). There wer e 16 males and 4 females. Assessments: Clinical (Ashworth spasticity r ating scale, scores for joint mobility, pain and frequency of spasms, Frenchay arm test (FAT)I and subjective (semi-quantitative rating scal e filled out by the patient). Only hand and finger flexors were inject ed. The maximum dosage was 150 U BOTOX(R) (25 U/muscle), the mean dosa ge was 92.1+/-31.6 U BOTOX(R). Results: Ashworth rating scale and join t mobility scores improved from a median value of 2 at baseline to a m edian value of 1 one month after treatment, FAT scores also improved f rom a median value of 0 at baseline to a median value of 1 one month a fter treatment (Kruskall-Wallis test p <0.01). Two-thirds of the patie nts rated their functional improvement as none or mild. Conclusions: O ur study confirmed that BTX-A has an anti-spastic effect but its funct ional impact needs further evaluation.